Search
Search Results
-
Lemborexant as a Potential Risk Factor for Sleep-Related Bruxism in a Patient with Complex Post-traumatic Stress Disorder: A Case Report
This article describes a case involving a 21-year-old woman with complex post-traumatic stress disorder (C-PTSD) who developed sleep-related bruxism...
-
Impact of zolpidem and lemborexant on sleep and morning symptoms when used as a single dose for polysomnography
This study evaluated the effect of zolpidem and lemborexant on sleep and morning symptoms in patients undergoing type-1 polysomnography for suspected...
-
The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
RationaleLemborexant (LEM) is a dual orexin receptor antagonist (DORA) approved in multiple countries including the USA, Japan, Canada, Australia,...
-
Daridorexant for the treatment of insomnia disorder: findings and implications
PurposeThe involvement of the orexin system in the physiopathology of insomnia has been rapidly increasing in understanding. In this sense,...
-
Discovery of New Transmitter Systems and Hence New Drug Targets
The development of medicationsMedications used to treat psychiatric conditions has largely proceeded through serendipity, where a potential drug to...
-
Sleep During Hypnotic Therapy
Insomnia is a significant public health burden with a prevalence rate of 5–50% in the general population. Evidence indicates that histaminergic,...
-
-
Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study
RationaleNovel compound with potent antagonistic activity against orexin receptors may be new treatment option for patients with insomnia.
...
-
Evaluating possible ‘next day’ impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial
Cannabis and its major constituents, Δ 9 -tetrahydrocannabinol (THC) and cannabidiol (CBD), are being widely used to treat sleep disturbances. However,...
-
Pharmacological Management of Insomnia
Insomnia is a highly prevalent condition associated with significant morbidity, reduction in quality of life, and increase in healthcare costs, and...
-
Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer’s disease
Failed proteostasis is a well-documented feature of Alzheimer’s disease, particularly, reduced protein degradation and clearance. However, the...
-
State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References
The Biopharmaceutics Drug Disposition Classification system (BDDCS) is a four-class approach based on water solubility and extent of...
-
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
While new drug approvals by the U.S. Food and Drug Administration (FDA) had remained stable or even increased in the first 2 years of the COVID-19...
-
Synthesis and clinical application of new drugs approved by FDA in 2022
The pharmaceutical industry had a glorious year in 2022, with a total of 37 new drugs including 20 new chemical entities (NCEs) and 17 new biological...
-
Residual effects of zopiclone on driving performance using a standardized driving simulator among healthy volunteers
RationaleThe effects of hypnotics on automobile driving have been attracting increasing attention. However, few driving simulators (DSs) have been...
-
Sleep Neurology’s Toolkit at the Crossroads: Challenges and Opportunities in Neurotherapeutics Lost and Found in Translation
We find ourselves at our present crossroads with a well-traveled toolkit, perhaps too well worn but with aspirational hopes and dreams for the field...
-
Treatment of insomnia associated with alcohol and opioid use: a narrative review
Substance use disorders (SUDs) are associated with profound sleep disturbances, including insomnia, sleep fragmentation, and circadian rhythm...
-
Periodontitis as a Risk Factor for Alzheimer’s Disease: The Experimental Journey So Far, with Hope of Therapy
Periodontitis and Alzheimer’s disease (AD) exist globally within the adult population. Given that the risk of AD incidence doubles within 10 years...
-
Exploring the Role of Orexinergic Neurons in Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disease affecting about 2% of the population. A neuropeptide, orexin, is linked with sleep...
